Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...

Interviewer: Amyloidosis is a rare and possibly debilitating disease, which affects about 4,000 people a year in the United States. If left untreated, the disease can cause severe organ damage, so ...

Transthyretin amyloidosis typically presents with entrapment neuropathy, polyneuropathy or heart failure; some patients may experience autonomic dysfunction or symptoms of central nervous system ...

In most cases, AA amyloidosis starts in the liver. In response to infection or inflammation, the liver produces high levels of SAA. These SAA proteins help carry immune cells to inflamed parts of the ...

Amyloidosis comprises a group of diseases characterized by the extracellular deposition of insoluble fibrillar proteins. This mechanism generates different clinical syndromes depending on the site and ...

Your DNA is composed of over 20,000 “coding genes,” which determine pretty much everything to do with your body and mind — from the color of your hair follicles to your cells’ ability to repair and ...

Care of patients with systemic immunoglobulin light chain (AL) amyloidosis has undergone transformative changes, leading to marked, steady progress in outcomes for patients over the past four decades.

Treatment for amyloidosis is complex and must be tailored to each individual, so it’s important to be treated at a specialized center with expertise in this disease. But because amyloidosis is rare, ...

The first signs and symptoms of hATTR amyloidosis with polyneuropathy can be recognized from the second decade of life, but most commonly, clinical manifestations of this disease develop in the third ...

The symptoms of amyloidosis vary widely due to the many different parts of the body that can be affected by the disease. If amyloid protein accumulates in a single part of the body, the disease is ...

Prothena is laying off almost two-thirds of its workforce as the Irish biotech navigates the fallout from giving up on its failed amyloidosis drug. In May, the company announced the failure of the ...